https://investors.abeonatherapeutics.com/ https://investors.abeonatherapeutics.com/news-events https://investors.abeonatherapeutics.com/news-events/press-releases https://investors.abeonatherapeutics.com/news-events/events https://investors.abeonatherapeutics.com/news-events/email-alerts https://investors.abeonatherapeutics.com/company-information https://investors.abeonatherapeutics.com/company-information/presentations https://investors.abeonatherapeutics.com/company-information/management-team https://investors.abeonatherapeutics.com/company-information/contacts https://investors.abeonatherapeutics.com/financial-information https://investors.abeonatherapeutics.com/financial-information/financial-results https://investors.abeonatherapeutics.com/stock-data https://investors.abeonatherapeutics.com/stock-data/stock-chart-detailed-quote https://investors.abeonatherapeutics.com/stock-data/historical-data https://investors.abeonatherapeutics.com/sec-filings https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings https://investors.abeonatherapeutics.com/sec-filings/annual-reports https://investors.abeonatherapeutics.com/sec-filings/quarterly-reports https://investors.abeonatherapeutics.com/sec-filings/section-16-filings https://investors.abeonatherapeutics.com/corporate-governance https://investors.abeonatherapeutics.com/corporate-governance/board-of-directors https://investors.abeonatherapeutics.com/corporate-governance/board-committees https://investors.abeonatherapeutics.com/corporate-governance/governance-documents https://investors.abeonatherapeutics.com/analyst-coverage https://investors.abeonatherapeutics.com/news-events/press-releases/detail/344/abeona-therapeutics-reports-first-quarter-2026-results-and-provides-pipeline-update 2026-05-13T07:30:04-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/343/abeona-therapeutics-announces-activation-of-childrens-hospital-of-philadelphia-as-a-new-qualified-treatment-center-for-zevaskyn 2026-05-11T08:30:02-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/342/abeona-therapeutics-announces-date-of-first-quarter-financial-results 2026-05-04T08:30:02-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/341/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2026-05-01T15:17:25-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/340/abeona-therapeutics-announces-appointment-of-keith-a-goldan-to-its-board-of-directors 2026-04-07T08:30:01-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/339/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2026-04-06T08:30:02-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/338/abeona-therapeutics-announces-new-qualified-treatment-center-for-zevaskyn-in-new-york 2026-04-02T08:30:03-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/337/abeona-therapeutics-reports-full-year-2025-financial-results-and-corporate-updates 2026-03-17T07:30:04-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/336/abeona-therapeutics-provides-business-update-highlighting-building-momentum-in-zevaskyn-commercial-launch 2026-03-09T07:30:01-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/335/abeona-therapeutics-announces-date-of-fourth-quarter-full-year-2025-financial-results-and-participation-in-upcoming-2026-leerink-global-healthcare-conference 2026-03-03T07:30:02-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/334/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2026-02-09T10:04:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/333/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-12-31T07:30:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/332/abeona-therapeutics-announces-appointment-of-mohamad-tabrizi-as-chief-business-officer 2025-12-15T07:30:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/331/abeona-therapeutics-announces-new-qualified-treatment-center-for-zevaskyn-in-texas 2025-12-11T07:30:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/330/abeona-therapeutics-announces-first-patient-treatment-with-zevaskyn-gene-therapy 2025-12-08T07:30:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/329/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-12-01T07:30:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/328/abeona-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-updates 2025-11-12T07:30:02-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/327/abeona-therapeutics-announces-date-of-third-quarter-financial-results-and-upcoming-investor-conference-participation 2025-11-07T07:30:02-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/326/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/325/abeona-therapeutics-announces-permanent-j-code-for-zevaskyn-prademagene-zamikeracel 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/324/abeona-therapeutics-appoints-james-a-gow-md-mba-ms-mhcm-as-senior-vice-president-head-of-clinical-development-medical-affairs 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/323/abeona-therapeutics-announces-abo-503-gene-therapy-for-x-linked-retinoschisis-xlrs-selected-by-fda-for-rare-disease-endpoint-advancement-rdea-pilot-program 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/322/abeona-therapeutics-and-childrens-hospital-colorado-announce-newest-treatment-center-for-zevaskyn-gene-therapy 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/321/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/320/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:25-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/319/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/318/abeona-therapeutics-reports-second-quarter-2025-financial-results-and-corporate-updates 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/317/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/316/zevaskyn-gene-therapy-now-available-at-new-qualified-treatment-center-in-san-francisco-bay-area 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/315/abeona-therapeutics-closes-sale-of-rare-pediatric-disease-priority-review-voucher-for-155-million 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/314/abeona-therapeutics-announces-option-exercise-by-beacon-therapeutics-for-novel-aav204-capsid-for-ophthalmology-gene-therapy 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/313/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/312/abeona-therapeutics-added-to-membership-of-u-s-small-cap-russell-2000-index-and-broad-market-russell-3000-index 2025-11-04T16:18:26-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/311/abeona-therapeutics-announces-publication-in-the-lancet-of-phase-3-viital-study-data-in-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/310/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/309/abeona-therapeuticsto-present-at-the-jefferies-global-healthcare-conference 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/308/abeona-therapeutics-reports-first-quarter-2025-financial-results-and-corporate-updates 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/307/update----abeona-therapeutics-and-lurie-childrens-open-first-center-for-zevaskyn-gene-therapy-to-treat-wounds-in-painful-skin-disorder 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/306/abeona-therapeutics-and-lurie-childrens-open-first-center-for-zevaskyntm-gene-therapy-to-treat-wounds-in-painful-skin-disorder 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/305/abeona-therapeutics-enters-into-agreement-to-sell-priority-review-voucher-for-155-million 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/304/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/303/u-s-fda-approves-zevaskyn-prademagene-zamikeracel-the-first-and-only-cell-based-gene-therapy-for-patients-with-recessive-dystrophic-epidermolysis-bullosa-rdeb 2025-11-04T16:18:27-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/302/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:28-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/301/abeona-therapeutics-reports-full-year-2024-financial-results-provides-pz-cel-regulatory-update-and-commercial-launch-plans 2025-11-04T16:18:28-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/300/abeona-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conference 2025-11-04T16:18:28-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/299/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:28-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/298/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:28-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/297/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:28-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/296/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:29-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/295/abeona-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-updates 2025-11-04T16:18:29-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/294/abeona-therapeutics-announces-fda-acceptance-of-bla-resubmission-of-pz-cel-for-the-treatment-of-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:29-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/293/abeona-therapeutics-announces-participation-in-november-investor-conferences 2025-11-04T16:18:29-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/292/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:29-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/291/abeona-therapeutics-completes-pz-cel-biologics-license-application-resubmission-to-u-s-food-and-drug-administration 2025-11-04T16:18:29-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/290/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/289/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/288/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/287/abeona-therapeutics-announces-appointment-of-bernhardt-zeiher-md-fccp-facp-and-eric-crombez-md-to-its-board-of-directors 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/286/abeona-therapeutics-announces-favorable-medicare-reimbursement-decisions-for-pz-cel 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/285/abeona-therapeutics-reports-second-quarter-2024-financial-results-and-concludes-type-a-meeting-with-fda-to-align-on-upcoming-pz-cel-bla-resubmission 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/284/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/283/abeona-therapeutics-and-beacon-therapeutics-announce-non-exclusive-agreement-for-beacon-to-evaluate-therapeutic-potential-of-abeonas-patented-aav204-capsid-for-select-ophthalmology-indications 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/282/abeona-therapeutics-to-present-at-the-stifel-virtual-cell-therapy-forum 2025-11-04T16:18:30-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/281/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:31-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/280/abeona-therapeutics-to-present-at-the-jefferies-global-healthcare-conference 2025-11-04T16:18:31-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/279/abeona-therapeutics-reports-first-quarter-2024-financial-results-and-recent-corporate-progress 2025-11-04T16:18:31-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/278/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:32-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/277/abeona-therapeutics-announces-pricing-of-75-million-underwritten-offering-of-common-stock-and-pre-funded-warrants 2025-11-04T16:18:32-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/276/abeona-therapeutics-provides-regulatory-update-on-pz-cel 2025-11-04T16:18:33-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/275/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:33-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/274/abeona-therapeutics-reports-full-year-2023-financial-results-and-announces-completion-of-fda-inspections 2025-11-04T16:18:33-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/273/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:34-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/272/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:34-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/271/abeona-therapeutics-announces-progress-update-on-pz-cel-biologics-license-application-bla 2025-11-04T16:18:34-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/270/abeona-therapeutics-announces-50-million-credit-facility 2025-11-04T16:18:34-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/269/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:34-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/268/abeona-therapeutics-announces-fda-accepts-and-grants-priority-review-for-pz-cel-biologics-license-application-bla 2025-11-04T16:18:34-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/267/abeona-therapeutics-reports-third-quarter-2023-financial-results-and-corporate-developments 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/266/abeona-therapeutics-announces-new-employee-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/265/abeona-therapeutics-submits-biologics-license-application-to-u-s-fda-seeking-priority-review-and-approval-of-eb-101-for-the-treatment-of-patients-with-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/264/abeona-therapeutics-appoints-madhav-vasanthavada-ph-d-m-b-a-as-chief-commercial-officer 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/263/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/262/abeona-therapeutics-announces-positive-pre-bla-meeting-with-fda-for-eb-101-and-plans-for-bla-submission 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/261/abeona-therapeutics-reports-second-quarter-2023-financial-results 2025-11-04T16:18:35-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/260/abeona-therapeutics-announces-submission-of-briefing-package-for-pre-biologics-license-application-bla-meeting-with-fda-in-august-2023 2025-11-04T16:18:36-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/259/abeona-therapeutics-joins-rare-disease-company-coalition 2025-11-04T16:18:36-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/258/abeona-therapeutics-announces-closing-of-25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2025-11-04T16:18:36-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/257/abeona-therapeutics-announces-25-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2025-11-04T16:18:36-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/256/abeona-therapeutics-announces-regulatory-update-on-biologics-license-application-bla-for-eb-101 2025-11-04T16:18:36-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/255/abeona-therapeutics-to-present-at-the-jefferies-healthcare-conference 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/254/abeona-therapeutics-announces-date-change-for-first-quarter-2023-portfolio-update-conference-call-to-may-24-2023 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/253/abeona-therapeutics-announces-new-preclinical-data-from-its-aav-ophthalmology-program-at-the-26th-annual-meeting-of-the-american-society-of-gene-cell-therapy-asgct 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/252/abeona-therapeutics-reports-first-quarter-2023-financial-results 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/251/abeona-therapeutics-announces-additional-phase-3-viital-study-results-for-eb-101-presented-at-the-international-societies-for-investigative-dermatology-2023-meeting 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/250/abeona-therapeutics-announces-multiple-abstracts-accepted-from-its-aav-ophthalmology-program-at-the-26th-annual-meeting-of-the-american-society-of-gene-cell-therapy-asgct 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/249/abeona-therapeutics-reports-full-year-2022-financial-results-and-provides-corporate-update 2025-11-04T16:18:37-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/248/abeona-therapeutics-announces-new-employee-inducement-grants 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/247/abeona-therapeutics-announces-acceptance-of-abstract-on-eb-101-phase-3-viital-study-results-for-oral-presentation-at-international-societies-for-investigative-dermatology-isid-2023-meeting 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/246/abeona-therapeutics-announces-update-on-aav-ophthalmology-program 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/245/abeona-therapeutics-reports-third-quarter-2022-financial-results 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/244/abeona-therapeutics-announces-35-million-private-placement-financing 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/243/abeona-therapeutics-announces-positive-topline-results-with-both-co-primary-endpoints-met-in-pivotal-phase-3-viital-study-of-eb-101 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/242/abeona-therapeutics-announces-database-lock-for-pivotal-phase-3-viital-study-of-eb-101-in-patients-with-recessive-dystrophic-epidermolysis-bullosa-rdeb 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/241/abeona-therapeutics-announces-completion-of-patient-follow-up-in-pivotal-phase-3-viital-study-of-eb-101-in-patients-with-recessive-dystrophic-epidermolysis-bullosa-rdeb 2025-11-04T16:18:38-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/240/abeona-therapeutics-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit 2025-11-04T16:18:39-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/239/abeona-therapeutics-to-participate-in-the-cantor-fitzgerald-cell-and-genetic-medicines-conference 2025-11-04T16:18:39-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/238/abeona-therapeutics-reports-second-quarter-2022-financial-results 2025-11-04T16:18:39-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/237/abeona-therapeutics-regains-compliance-with-nasdaq-listing-requirements 2025-11-04T16:18:39-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/236/abeona-therapeutics-to-present-at-the-jefferies-healthcare-conference 2025-11-04T16:18:40-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/235/abeona-therapeutics-granted-second-180-day-period-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule 2025-11-04T16:18:40-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/234/ultragenyx-acquires-global-rights-to-aav-gene-therapy-abo-102-for-sanfilippo-syndrome-type-a-mps-iiia-from-abeona-therapeutics 2022-05-17T08:13:19-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/233/abeona-therapeutics-reports-first-quarter-2022-financial-results 2025-11-04T16:18:40-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/232/abeona-therapeutics-announces-aav204-a-novel-aav-capsid-demonstrated-robust-macular-transduction-following-para-retinal-administration-in-non-human-primates 2025-11-04T16:18:40-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/231/abeona-therapeutics-announces-presentation-at-the-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting 2025-11-04T16:18:40-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/230/abeona-therapeutics-announces-pricing-of-25-million-private-placement-of-convertible-redeemable-preferred-stock 2025-11-04T16:18:40-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/229/abeona-therapeutics-announces-strategy-update-and-2021-financial-results 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/228/abeona-therapeutics-to-participate-in-the-cantor-fitzgerald-virtual-rare-orphan-disease-summit 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/227/abeona-therapeutics-achieves-target-enrollment-in-pivotal-phase-3-viital-study-of-eb-101-in-rdeb 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/226/abeona-therapeutics-issues-letter-to-shareholders 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/225/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-warrants 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/224/abeona-therapeutics-announces-public-offering-of-common-stock-and-warrants 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/223/abeona-therapeutics-announces-support-of-eb-research-partnerships-venture-into-cures-event-to-raise-awareness-for-education-and-research-of-epidermolysis-bullosa 2025-11-04T16:18:41-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/222/abeona-therapeutics-announces-presentation-on-pivotal-transpher-a-study-of-abo-102-in-mps-iiia-at-the-14th-iciem-conference 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/221/abeona-therapeutics-announces-participation-at-the-jefferies-london-healthcare-conference 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/220/abeona-therapeutics-reports-third-quarter-financial-results 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/219/abeona-therapeutics-to-present-at-jefferies-gene-therapyediting-summit 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/218/abeona-therapeutics-announces-clinical-data-presentations-at-upcoming-scientific-congresses 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/217/abeona-therapeutics-appoints-gene-therapy-quality-leader-jon-voss-as-vice-president-head-of-quality 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/216/abeona-announces-new-chairman-executive-leadership-promotions-and-key-talent-additions-for-final-push-towards-two-biologics-license-application-bla-filings 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/215/abeona-therapeutics-to-present-at-upcoming-investor-conferences 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/214/abeona-therapeutics-appoints-edward-carr-as-chief-financial-officer 2025-11-04T16:18:42-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/213/abeona-therapeutics-reports-second-quarter-financial-results 2025-11-04T16:18:43-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/212/abeona-therapeutics-announces-successful-type-b-meeting-with-u-s-fda-for-abo-102-aav-based-gene-therapy-in-sanfilippo-syndrome-type-a-mps-iiia 2025-11-04T16:18:43-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/211/abeona-therapeutics-announces-new-mri-data-showing-increased-brain-volume-in-young-patients-with-sanfilippo-syndrome-type-a-mps-iiia-after-treatment-with-abo-102-gene-therapy 2025-11-04T16:18:43-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/210/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:43-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/209/abeona-therapeutics-announces-updated-eb-101-phase-12a-clinical-results-in-recessive-dystrophic-epidermolysis-bullosa-at-the-society-for-pediatric-dermatology-46th-annual-meeting 2025-11-04T16:18:43-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/208/abeona-therapeutics-to-present-at-jefferies-virtual-healthcare-conference 2025-11-04T16:18:44-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/207/abeona-therapeutics-issues-letter-to-stockholders 2025-11-04T16:18:44-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/206/abeona-therapeutics-appoints-head-of-research-clinical-development 2025-11-04T16:18:44-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/205/abeona-therapeutics-reports-first-quarter-financial-results 2025-11-04T16:18:44-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/204/abeona-therapeutics-announces-presentation-on-new-preclinical-data-supporting-the-potential-of-cre-mediated-dual-aav-vector-technology-to-enable-delivery-of-large-genes-targeted-for-treatment-of-stargardt-disease-at-arvo-2021-annual-meeting 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/203/abeona-therapeutics-appoints-two-industry-leaders-as-new-independent-members-to-its-board-of-directors 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/202/abeona-therapeutics-announces-appointment-of-two-new-independent-members-to-its-board-of-directors 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/201/abeona-therapeutics-announces-2020-financial-results-and-recent-operational-progress 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/200/abeona-therapeutics-announces-appointment-of-michael-amoroso-as-chief-executive-officer 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/199/abeona-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/198/new-positive-phase-12-interim-data-presented-at-worldsymposium-shows-neurocognitive-development-of-young-mps-iiia-patients-preserved-up-to-three-years-following-treatment-with-abeonas-abo-102-gene-therapy 2025-11-04T16:18:45-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/197/abeona-therapeutics-announces-clinical-investigator-webinar-to-review-abo-102-and-abo-101-clinical-data-presented-at-the-17th-annual-worldsymposium 2025-11-04T16:18:46-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/196/abeona-therapeutics-announces-successful-type-b-meeting-with-fda-for-pivotal-phase-3-viital-study-of-eb-101-in-recessive-dystrophic-epidermolysis-bullosa-rdeb 2025-11-04T16:18:46-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/195/abeona-therapeutics-announces-acceptance-of-late-breaker-abstracts-highlighting-new-clinical-data-for-novel-aav-based-gene-therapies-in-mps-iiia-and-mps-iiib-at-worldsymposium 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/194/abeona-therapeutics-reports-third-quarter-financial-results 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/193/abeona-therapeutics-announces-the-appointment-of-michael-amoroso-as-chief-operating-officer 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/192/abeona-therapeutics-board-of-directors-forms-special-committee-to-oversee-operations-develop-strategic-direction-and-leadership-plan 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/191/abeona-therapeutics-announces-leadership-and-board-transitions 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/190/abeona-therapeutics-to-participate-in-upcoming-investor-conferences 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/189/abeona-therapeutics-and-taysha-gene-therapies-enter-into-licensing-and-inventory-purchase-agreements-for-abo-202-a-clinical-stage-novel-one-time-gene-therapy-for-cln1-disease 2025-11-04T16:18:47-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/188/abeona-therapeutics-reports-second-quarter-financial-results-and-business-updates 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/187/abeona-therapeutics-announces-two-presentations-related-to-its-rdeb-clinical-program-at-the-society-for-pediatric-dermatology-45th-annual-meeting 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/186/abeona-therapeutics-announces-appointment-of-michael-amoroso-as-chief-commercial-officer 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/185/abeona-therapeutics-reinitiates-enrollment-in-eb-101-pivotal-phase-3-viital-study-in-rdeb-after-covid-19-related-pause-and-announces-progress-in-patient-enrollment-in-mps-iii-studies 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/184/abeona-therapeutics-announces-upcoming-data-presentations-at-the-society-for-pediatric-dermatology-45th-annual-meeting 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/183/abeona-therapeutics-further-strengthens-board-with-appointment-of-two-new-independent-directors 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/182/abeona-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference 2025-11-04T16:18:48-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/181/abeona-therapeutics-reports-first-quarter-financial-results-and-business-updates 2025-11-04T16:18:49-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/180/abeona-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2025-11-04T16:18:49-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/179/abeona-therapeutics-appoints-brian-pereira-and-shawn-tomasello-to-the-board-of-directors 2025-11-04T16:18:49-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/178/abeona-therapeutics-stakeholder-letter-in-response-to-the-covid-19-pandemic 2025-11-04T16:18:49-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/177/abeona-therapeutics-announces-first-patient-treated-in-pivotal-phase-iii-clinical-trial-evaluating-eb-101-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:50-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/176/abeona-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and-business-updates 2025-11-04T16:18:50-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/175/abeona-therapeutics-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference 2025-11-04T16:18:50-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/174/abeona-therapeutics-announces-positive-interim-data-from-mps-iii-gene-therapy-programs-presented-at-worldsymposium 2025-11-04T16:18:50-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/173/abeona-therapeutics-announces-participation-in-inaugural-world-congress-on-epidermolysis-bullosa 2025-11-04T16:18:50-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/172/abeona-therapeutics-announces-issuance-of-u-s-patent-for-aim-capsids 2025-11-04T16:18:51-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/171/abeona-therapeutics-initiates-pivotal-phase-3-clinical-trial-evaluating-eb-101-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:51-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/170/abeona-announces-closing-of-103-5-million-underwritten-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2025-11-04T16:18:51-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/169/abeona-announces-pricing-of-public-offering-of-common-stock-and-prefunded-warrants 2025-11-04T16:18:51-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/168/abeona-therapeutics-receives-european-medicines-agency-prime-designation-for-abo-102-gene-therapy-in-mps-iiia 2025-11-04T16:18:51-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/167/abeona-therapeutics-announces-public-offering-of-common-stock-and-pre-funded-warrants 2025-11-04T16:18:52-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/166/abeona-therapeutics-cleared-to-initiate-pivotal-phase-3-clinical-trial-evaluating-eb-101-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:52-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/165/abeona-therapeutics-reports-third-quarter-2019-financial-results-and-business-updates 2025-11-04T16:18:53-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/164/abeona-therapeutics-announces-presentations-at-the-27th-european-society-of-gene-and-cell-therapy-esgct-congress 2025-11-04T16:18:54-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/163/abeona-therapeutics-announces-publication-of-positive-long-term-data-from-phase-12a-clinical-trial-evaluating-eb-101-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:54-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/162/abeona-therapeutics-provides-regulatory-update-ahead-of-pivotal-phase-3-clinical-trial-for-eb-101-in-recessive-dystrophic-epidermolysis-bullosa 2025-11-04T16:18:54-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/161/abeona-therapeutics-announces-strategic-review 2025-11-04T16:18:54-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/160/abeona-therapeutics-reports-second-quarter-2019-financial-results-and-business-updates 2025-11-04T16:18:54-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/159/abeona-therapeutics-announces-positive-interim-data-from-the-abo-102-phase-12-gene-therapy-clinical-trial-in-mps-iiia 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/158/abeona-therapeutics-appoints-dr-victor-paulus-senior-vice-president-of-regulatory-affairs 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/157/abeona-therapeutics-receives-fda-fast-track-designation-for-abo-202-aav9-gene-therapy-in-cln1-disease 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/156/abeona-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-abo-202-gene-therapy-in-cln1-disease 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/155/abeona-therapeutics-treats-first-patient-in-second-cohort-of-phase-12-clinical-trial-for-abo-101-in-sanfilippo-syndrome-type-b-mps-iiib 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/154/abeona-therapeutics-reports-first-quarter-2019-financial-results-and-business-highlights 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/153/abeona-therapeutics-announces-presentation-of-eb-101-data-at-society-for-investigative-dermatology-annual-meeting 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/152/abeona-therapeutics-announces-participation-in-upcoming-investor-conferences 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/151/abeona-therapeutics-reports-preclinical-data-demonstrating-broad-therapeutic-potential-of-aim-gene-therapy-in-retinal-diseases-at-association-for-research-in-vision-and-ophthalmology-annual-meeting 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/150/abeona-therapeutics-to-report-new-preclinical-data-demonstrating-therapeutic-potential-of-abo-401-for-treatment-of-cystic-fibrosis-at-american-society-of-gene-and-cell-therapy-annual-meeting 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/149/abeona-therapeutics-to-present-data-for-abo-401-in-cystic-fibrosis-and-retinal-disorders-at-the-american-society-of-gene-and-cell-therapy-annual-meeting 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/148/abeona-therapeutics-receives-fda-fast-track-designation-for-abo-101-for-treatment-of-sanfilippo-syndrome-type-b-mps-iiib 2025-11-04T16:18:55-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/147/abeona-therapeutics-reports-fourth-quarter-and-full-year-2018-financial-results 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/146/abeona-therapeutics-announces-participation-in-8th-annual-svb-leerink-global-healthcare-conference 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/145/abeona-therapeutics-appoints-joo-siffert-m-d-chief-executive-officer 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/144/abeona-therapeutics-to-present-new-supportive-data-for-novel-gene-therapies-at-worldsymposium 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/143/abeona-therapeutics-strengthens-financial-leadership-with-new-executive-appointments 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/142/abeona-therapeutics-details-pathway-for-advancing-lead-clinical-programs-and-unveils-new-cystic-fibrosis-program-born-from-next-generation-aim-vector-platform-at-2018-rd-day 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/141/abeona-therapeutics-to-host-rd-day-on-december-6-2018 2025-11-04T16:18:56-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/140/abeona-therapeutics-announces-ceo-transition 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/139/abeona-announces-participation-at-the-jefferies-2018-london-healthcare-conference 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/138/abeona-therapeutics-reports-third-quarter-2018-financial-results-and-business-highlights 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/137/abeona-therapeutics-and-regenxbio-announce-worldwide-exclusive-licenses-for-the-treatment-of-four-rare-lysosomal-storage-disorders-using-nav-aav9-vector 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/136/abeona-therapeutics-appoints-joo-siffert-m-d-head-of-research-and-development-and-chief-medical-officer 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/135/abeona-announces-participation-at-upcoming-conferences 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/134/abeona-therapeutics-announces-authorization-to-commence-phase-12-gene-therapy-clinical-study-for-patients-with-mps-iiib-in-spain 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/133/abeona-announces-participation-at-upcoming-conferences 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/132/abeona-therapeutics-reports-second-quarter-2018-financial-results-and-business-highlights 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/131/abeona-therapeutics-announces-leadership-appointments-with-max-colao-as-chief-commercial-officer 2025-11-04T16:18:57-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/130/abeona-therapeutics-announces-upcoming-presentation-at-jefferies-2018-global-healthcare-conference 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/129/abeona-therapeutics-announces-opening-of-commercial-gene-cell-therapy-manufacturing-facility-in-ohio 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/128/abeona-therapeutics-provides-clinical-update-on-mps-iiia-gene-therapy-trial-at-the-21st-annual-asgct-meeting 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/127/abeona-reports-update-from-eb-101-gene-therapy-in-epidermolysis-bullosa-at-21st-annual-asgct-meeting 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/126/abeona-therapeutics-announces-appointment-of-stefano-buono-and-richard-van-duyne-to-its-board-of-directors 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/125/abeona-therapeutics-reports-first-quarter-2018-financial-results-and-business-highlights 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/124/abeona-therapeutics-announces-upcoming-presentations 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/123/abeona-announces-fda-grants-rmat-designationto-abo-102-gene-therapy-in-mps-iiia 2025-11-04T16:18:58-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/122/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-202-gene-therapy-program-in-batten-disease 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/117/abeona-therapeutics-appoints-carsten-thiel-ph-d-as-chief-executive-officer 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/116/abeona-therapeutics-reports-fourth-quarter-2017-financial-results-and-business-highlights 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/115/abeona-therapeutics-receives-fda-rare-pediatric-disease-designation-for-abo-202-gene-therapy-program-in-cln1-disease 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/114/abeona-therapeutics-announces-upcoming-conference-participation 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/113/abeona-therapeutics-receives-fda-orphan-drug-designation-for-abo-202-gene-therapy-program-in-infantile-batten-disease 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/112/abeona-therapeutics-reports-top-line-data-from-phase-12-gene-therapy-trial-in-mps-iiia 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/111/abeona-therapeutics-reports-on-initial-safety-and-biopotency-signals-in-mps-iiib-gene-therapy-clinical-trial 2025-11-04T16:18:59-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/110/abeona-therapeutics-announces-upcoming-presentations-at-the-14th-annual-worldsymposium 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/109/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-epidermolysis-bullosa 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/108/abeona-therapeutics-enrolls-first-patient-in-abo-101-phase-12-clinical-trial-for-mps-iiib 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/107/abeona-reports-third-quarter-2017-financial-resultsand-recent-business-highlights 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/106/abeona-enrolls-first-subject-in-spain-in-ongoing-phase-12-clinical-trial-in-mps-iiia 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/105/abeona-announces-closing-of-92-million-underwritten-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/104/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/103/abeona-therapeutics-announces-public-offering-of-common-stock 2025-11-04T16:19:00-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/102/abeona-announces-13-85m-grant-from-leading-sanfilippo-syndrome-foundations-for-clinical-development-of-mps-iii-gene-therapies 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/101/abeona-therapeutics-enrolls-first-two-patients-in-pivotal-expansion-of-phase-12-clinical-trial-in-mps-iiia 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/100/abeona-announces-top-line-one-year-data-from-abo-102-mps-iiia-trial-at-arms-cell-gene-meeting-on-the-mesa 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/99/abeona-therapeutics-announces-dedication-of-commercial-gene-therapy-manufacturing-facility-in-cleveland-ohio 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/98/abeona-therapeutics-and-brammer-bio-announce-collaboration-for-commercial-translation-of-abo-102 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/97/abeona-therapeutics-announces-upcoming-conference-participation 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/96/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-epidermolysis-bullosa 2025-11-04T16:19:01-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/95/abeona-therapeutics-to-host-gene-therapy-rd-day-on-october-11-2017 2025-11-04T16:19:02-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/94/abeona-therapeutics-reports-second-quarter-2017-financial-results-and-recent-business-highlights 2025-11-04T16:19:02-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/93/abeona-therapeutics-announces-appointment-of-juan-ruiz-as-chief-medical-officer 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/92/abeona-therapeutics-receives-guidance-from-fda-to-commence-pivotal-phase-3-for-eb-101-gene-therapy-for-patients-with-epidermolysis-bullosa 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/91/abeona-therapeutics-receives-fda-orphan-drug-designation-for-abo-201-juvenile-batten-disease-gene-therapy-program 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/90/abeona-therapeutics-to-present-at-the-jefferies-2017-global-healthcare-conference 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/89/abeona-therapeutics-receives-rare-pediatric-disease-designation-for-eb-101-gene-therapy-product-for-patients-with-epidermolysis-bullosa 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/88/abeona-therapeutics-receives-fda-orphan-drug-designation-for-eb-101-gene-therapy-product-for-patients-with-epidermolysis-bullosa 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/87/abeona-therapeutics-to-present-at-multiple-upcoming-conferences 2025-11-04T16:19:03-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/86/abeona-therapeutics-reports-first-quarter-2017-financial-results-and-recent-business-highlights 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/85/abeona-therapeutics-announces-top-line-data-for-abo-102-phase-12-mps-iiia-gene-therapy-trial-at-asgct 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/84/abeona-therapeutics-receives-regulatory-approval-to-initiate-clinical-trial-in-australia-with-abo-102-gene-therapy-for-patients-with-mps-iiia 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/83/abeona-therapeutics-announces-gene-therapy-clinical-trial-and-preclinical-program-presentations-at-asgct-20th-annual-meeting 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/82/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa-from-the-society-for-investigative-dermatology-conference 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/81/abeona-therapeutics-announces-eb-101-clinical-update-to-be-presented-at-the-society-for-investigative-dermatology-annual-meeting 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/80/abeona-to-present-at-multiple-upcoming-conferences 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/79/abeona-announces-rare-disease-gene-therapy-symposium-with-the-new-york-academy-of-sciences 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/78/abeona-therapeutics-reports-q4-2016-financial-results-and-business-highlights 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/77/abeona-therapeutics-to-present-at-multiple-upcoming-investor-conferences 2025-11-04T16:19:04-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/76/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-eb-101-gene-therapy-clinical-trial-for-epidermolysis-bullosa 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/75/abeona-therapeutics-to-present-at-the-cowen-and-company-37th-annual-health-care-conference 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/74/abeona-therapeutics-to-present-at-maxim-group-llc-biotech-investor-partnering-conference-in-shanghai 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/73/abeona-therapeutics-announces-dismissal-of-securities-class-action-lawsuit 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/72/abeona-therapeutics-to-present-at-the-2017-rbc-capital-markets-global-healthcare-conference-and-3rd-annual-crispr-congress 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/71/abeona-therapeutics-provides-update-from-abo-102-phase-12-mps-iiia-clinical-trial-at-the-13th-annual-worldsymposium-2017 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/70/abeona-therapeutics-announces-presentations-and-posters-at-the-13th-annual-worldsymposium-2017 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/69/abeona-therapeutics-enrolls-first-high-dose-subject-in-ongoing-phase-12-gene-therapy-clinical-trial-insanfilippo-syndrome-type-a 2025-11-04T16:19:05-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/68/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-101-gene-therapy-in-sanfilippo-syndrome-type-b 2025-11-04T16:19:06-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/67/abeona-therapeutics-to-present-at-phacilitate-cell-gene-therapy-world-2017 2025-11-04T16:19:06-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/66/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-201-gene-therapy-program-in-juvenile-batten-disease 2025-11-04T16:19:06-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/65/abeona-therapeutics-to-present-at-2016-genetic-rx-boston-biotech-conference-at-harvard-medical-school 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/64/abeona-therapeutics-to-present-at-world-orphan-and-drug-congress-europe-2016 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/63/abeona-therapeutics-announces-third-quarter-2016-financial-results-and-recent-clinical-highlights 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/62/abeona-therapeutics-honored-with-partner-in-progress-award-from-debra-of-america 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/61/abeona-therapeutics-to-present-at-alliance-of-regenerative-medicine-4th-annual-advanced-therapies-investor-day-in-london-uk 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/60/abeona-therapeutics-announces-jama-publication-of-positive-phase-1-study-results-for-eb-101-gene-therapy-clinical-trial-for-epidermolysis-bullosa 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/59/abeona-therapeutics-inc-announces-closing-of-its-underwritten-offering-of-common-stock 2025-11-04T16:19:07-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/58/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/57/abeona-therapeutics-announces-public-offering-of-common-stock 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/56/abeona-therapeutics-announces-fast-track-designation-from-fda-for-abo-102-in-sanfilippo-syndrome-type-a 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/55/abeona-therapeutics-provides-update-from-abo-102-phase-12-mps-iiia-clinical-trial-at-orphan-drugs-rare-disease-conference-london-uk 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/54/abeona-therapeutics-receives-orphan-drug-designation-in-the-european-union-for-abo-102-gene-therapy-in-sanfilippo-syndrome-type-a 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/53/abeona-therapeutics-to-present-top-line-data-of-low-dose-cohort-for-abo-102-in-phase-12-clinical-trial-for-mps-iiia-patients-at-upcoming-orphan-drugs-and-rare-disease-congress-october-19-20th-in-london-uk 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/52/abeona-therapeutics-announces-publication-of-preclinical-data-supporting-clinical-translation-of-juvenile-batten-disease-gene-therapy 2025-11-04T16:19:08-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/51/abeona-therapeutics-announces-data-safety-monitoring-board-approves-abo-102-dose-escalation-for-second-cohort-in-phase-12-clinical-trial-for-sanfilippo-syndrome-type-a 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/50/abeona-therapeutics-to-present-at-jefferies-gene-editing-gene-therapy-summit 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/49/abeona-therapeutics-to-present-at-cell-gene-meeting-on-the-mesa 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/48/abeona-therapeutics-enrolls-first-patient-in-phase-2-for-eb-101-gene-therapy-clinical-trial-for-epidermolysis-bullosa 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/47/abeona-therapeutics-to-present-at-ladenburg-thalmann-2016-healthcare-conference 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/46/abeona-therapeutics-announces-licensing-of-the-aimtm-next-generation-aav-gene-therapy-vector-platform-from-the-university-of-north-carolina-at-chapel-hill 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/45/abeona-therapeutics-to-present-at-2016-aegis-growth-conference 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/44/abeona-therapeutics-announces-publication-of-preclinical-data-supporting-clinical-translation-of-mps-iiia-gene-therapy 2025-11-04T16:19:09-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/43/abeona-therapeutics-enrolls-5th-patient-in-phase-12-gene-therapy-clinical-trial-for-epidermolysis-bullosa 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/42/abeona-therapeutics-to-present-at-rodman-renshaw-18th-annual-global-investment-conference 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/41/abeona-therapeutics-to-present-at-landmark-angels-6th-annual-investing-for-cures-2016-conference 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/40/abeona-therapeutics-completes-enrollment-of-low-dose-cohort-for-abo-102-in-phase-12-clinical-trial-for-mps-iiia-patients 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/39/abeona-therapeutics-announces-second-quarter-2016-financial-results-and-recent-clinical-highlights 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/38/abeona-therapeutics-eb-research-partnership-and-eb-medical-research-foundation-to-collaborate-on-epidermolysis-bullosa-eb-treatments 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/37/abeona-therapeutics-announces-european-regulatory-approval-for-phase-12-gene-therapy-clinical-study-for-patients-with-sanfilippo-syndrome-type-a-mps-iiia 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/36/abeona-therapeutics-provides-update-on-initial-subjects-in-sanfilippo-type-a-gene-therapy-trial-demonstrating-encouraging-early-biopotency-signals 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/35/abeona-therapeutics-to-present-at-cantor-fitzgeralds-2nd-annual-healthcare-conference 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/34/abeona-therapeutics-to-present-at-jefferies-2016-global-healthcare-conference 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/33/abeona-therapeutics-to-present-at-2016-bio-international-convention 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/32/abeona-therapeutics-announces-fda-allowance-of-investigational-new-drug-ind-for-phase-12-clinical-study-with-abo-101-gene-therapy-for-patients-with-sanfilippo-syndrome-type-b-mps-iiib 2025-11-04T16:19:10-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/31/abeona-therapeutics-to-present-at-ubs-2016-global-healthcare-conference 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/30/abeona-therapeutics-doses-first-patient-in-phase-12-trial-with-abo-102-gene-therapy-for-patients-with-sanfilippo-syndrome-type-a-mps-iiia 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/29/abeona-therapeutics-announces-first-quarter-2016-summary-financial-results-and-recent-operational-highlights 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/28/abeona-therapeutics-appoints-christine-silverstein-as-vice-president-of-investor-relations 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/27/abeona-therapeutics-to-present-at-gene-cell-and-molecular-therapies-for-inherited-metabolic-diseases-meeting 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/26/abeona-therapeutics-to-present-at-alliance-of-regenerative-medicines-arm-4th-annual-cell-gene-therapy-investor-day 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/25/abeona-therapeutics-to-present-at-the-28th-annual-roth-conference 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/24/abeona-therapeutics-announces-fourth-quarter-and-full-year-2015-summary-financial-results-and-recent-operational-highlights 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/23/abeona-therapeutics-highlights-new-preclinical-juvenile-neuronal-ceroid-lipofuscinosis-jncl-data-at-worldsymposiumtm-2016 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/22/abeona-therapeutics-announces-fda-allowance-of-investigational-new-drug-ind-for-systemic-aav-phase-12-clinical-study-with-abo-102-gene-therapy-for-patients-with-sanfilippo-syndrome-type-a-mps-iiia 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/21/abeona-therapeutics-inc-to-present-on-crisprcas9-technology-platform-progress-at-crispr-precision-gene-editing-congress 2025-11-04T16:19:11-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/20/abeona-therapeutics-to-present-at-source-capital-groups-2016-disruptive-growth-healthcare-conference 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/19/abeona-therapeutics-to-present-at-the-18th-annual-bio-ceo-investor-conference 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/18/abeona-therapeutics-announces-initial-european-regulatory-approvals-for-phase-12-gene-therapy-clinical-studies-for-patients-with-sanfilippo-syndromes-type-a-mps-iiia-and-type-b-mps-iiib 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/17/abeona-therapeutics-to-present-at-piper-jaffray-27th-annual-healthcare-conference 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/16/abeona-therapeutics-to-present-at-jefferies-2015-global-healthcare-conference 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/15/abeona-therapeutics-reports-financial-results-and-highlights-for-third-quarter-2015 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/14/abeona-therapeutics-announces-license-for-next-generation-aav-delivery-vector-for-fanconi-anemia-and-rare-blood-disease-platform 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/13/abeona-therapeutics-to-present-at-2015-stem-cell-meeting-on-the-mesa 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/12/abeona-therapeutics-to-present-at-2015-rodman-renshaw-annual-global-investment-conference 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/11/abeona-therapeutics-to-present-at-the-2015-sidoti-emerging-growth-conference 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/10/abeona-therapeutics-announces-recent-highlights-and-second-quarter-2015-conference-call 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/9/abeona-therapeutics-announces-closing-of-upsized-15-5-million-equity-financing-with-institutional-investors-and-management 2025-11-04T16:19:12-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/8/abeona-therapeutics-announces-8-5-million-equity-financing-with-current-institutional-investors-and-directors 2025-11-04T16:19:13-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/7/abeona-therapeutics-provides-update-on-sdftm-salt-diafiltration-plasma-fractionation-products 2025-11-04T16:19:13-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/6/abeona-therapeutics-raises-additional-4-6-million-through-warrant-exercises-in-q2-15 2025-11-04T16:19:13-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/5/abeona-therapeutics-set-to-join-russell-global-russell-3000r-and-russell-microcapr-indexes 2025-11-04T16:19:13-05:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/121/abeona-therapeutics-raises-foundation-led-3-6m-to-develop-therapies-for-children-suffering-from-rare-sanfilippo-diseases 2018-04-05T18:27:49-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/120/abeona-therapeutics-receives-u-s-orphan-drug-designations-for-treatment-of-sanfilippo-syndromes-a-and-b 2018-04-05T18:27:48-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/119/abeona-therapeutics-closes-750000-in-seed-round-to-develop-therapies-for-children-suffering-from-rare-sanfilippo-diseases 2018-04-05T18:27:48-04:00 https://investors.abeonatherapeutics.com/news-events/press-releases/detail/118/abeona-therapeutics-and-nationwide-childrens-hospital-receive-prestigious-global-genes-champions-of-hope-award-for-patient-advocacy 2018-04-05T18:27:47-04:00 https://investors.abeonatherapeutics.com/news-events/events/detail/20260612-annual-meeting-of-stockholders 2026-04-27T17:29:27-04:00 https://investors.abeonatherapeutics.com/news-events/events/detail/20260513-first-quarter-2026-earnings-call 2026-05-04T09:53:55-04:00 https://investors.abeonatherapeutics.com/news-events/events/detail/20260317-full-year-2025-results-and-business-update-conference-call 2026-03-03T09:45:42-05:00 https://investors.abeonatherapeutics.com/news-events/events/detail/20260310-2026-leerink-global-healthcare-conference 2026-03-03T09:48:34-05:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-022614/form10-q.htm 2026-05-13T07:39:34-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-022610/form8-k.htm 2026-05-13T07:31:49-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-022332/ownership.html 2026-05-11T18:37:08-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001972481-26-000150/primary_doc.html 2026-05-11T16:25:16-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-021127/formdefa14a.htm 2026-05-04T16:56:39-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-019340/primary_doc.html 2026-04-28T16:16:39-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-019156/0001493152-26-019156.pdf 2026-04-27T16:32:39-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-019153/formdef14a.htm 2026-04-27T16:31:53-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-017879/formpre14a.htm 2026-04-17T16:32:29-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-015456/ownership.html 2026-04-07T08:47:39-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-015453/ownership.html 2026-04-07T08:45:48-04:00 https://investors.abeonatherapeutics.com/sec-filings/all-sec-filings/content/0001493152-26-015451/form8-k.htm 2026-04-07T08:36:09-04:00 https://investors.abeonatherapeutics.com/company-information/presentations/detail/5764/topline-results-from-eb-101-pivotal-phase-3-viital-study 2026-05-13T16:06:12-04:00 https://investors.abeonatherapeutics.com/company-information/presentations/detail/6011/corporate-presentation 2026-05-13T16:06:12-04:00